Breaking the cycle of hard-to-heal wounds: the role of autologous whole blood clot therapy
Journal of Wound Care · 02.05.2026 · 35 (5) · 409-415
DOI: 10.12968/jowc.2025.0325 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Wound Care, erschienen am 02.05.2026. Verfasst von Robert J Snyder. Beteiligte Einrichtung: Cardiff University School of Medicine, Cardiff, Wales, UK. Hauptthemen laut MEDLINE: Wound Healing, Diabetic Foot, Blood Transfusion, Autologous, Wounds and Injuries. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Hard-to-heal (chronic) wounds pose significant challenges in healthcare due to their prolonged inflammatory phase and impaired healing processes. These wounds, commonly associated with diabetes, vascular insufficiency or impaired mobility, fail to progress through the orderly phases of haemostasis, inflammation, proliferation and remodelling. Persistent inflammation, driven by M1 macrophages, neutrophils and proteases, disrupts extracellular matrix (ECM) reconstruction and degrades growth factors and cytokines, halting healing. Conventional treatments often fail to address the underlying pathophysiology, prompting interest in advanced autologous therapies. Autologous whole blood clot (AWBC), an innovative autologous therapy, activates the patient's blood to create a biological scaffold rich in growth factors and cytokines. This scaffold promotes wound healing by supporting ECM reconstruction, causing inflammatory M1 macrophages to transition to regenerative M2 macrophages, and enhancing neutrophil clearance. The objective of this review was to summarise the current clinical evidence and elucidate the proposed biological mechanisms by which AWBC promotes healing in hard-to-heal wounds. Clinical studies have demonstrated AWBC's efficacy across multiple wound types, including diabetic foot ulcers, pressure ulcers and surgical wounds. With a robust safety profile, minimal risk of adverse reactions and reported efficacy, AWBC offers a transformative solution for hard-to-heal wound management, addressing unmet clinical needs and improving patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiff University School of Medicine, Cardiff, Wales, UK.
Zitieren
APA
Snyder, R. J. (2026). Breaking the cycle of hard-to-heal wounds: the role of autologous whole blood clot therapy. Journal of Wound Care, 35(5), 409-415. https://doi.org/10.12968/jowc.2025.0325
Vancouver
Snyder RJ. Breaking the cycle of hard-to-heal wounds: the role of autologous whole blood clot therapy. Journal of Wound Care. 2026;35(5):409-415. doi:10.12968/jowc.2025.0325
BibTeX
@article{Snyder2026,
author = {Snyder, Robert J},
title = {Breaking the cycle of hard-to-heal wounds: the role of autologous whole blood clot therapy},
journal = {Journal of Wound Care},
year = {2026},
volume = {35},
number = {5},
pages = {409--415},
doi = {10.12968/jowc.2025.0325}
}
EUVIMED